To request pricing for high-throughput use, please complete this short form.
To request pricing for portable on-site testing using our Franklin™ thermocyclers, please complete this short form.
Biomeme SARS-CoV-2 Tests detect the RNA of severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID-19). Two RNA targets for the novel coronavirus are multiplexed together with Biomeme's process control assay for RNA extraction and RT-PCR (MS2). Assay targets include:
- SARS-CoV-2-Orf1ab gene
- SARS-CoV-2-S gene
- RNA Process Control (RNA extraction and RT-PCR control utilizing MS2 bacteriophage)
Our tests come in 3 different form factors for you to choose from:
- Go-Strips (96 rxns per order): Each order consists of a single pouch containing a pre-cut and pre-aliquoted tray of (32) 3-well Go-Strips with void filling caps. Each well contains a 20 µL lyophilized triplex reaction.
- Go-Plates (96 rxns per order): Each order consists of a single pouch containing a 96-well Go-Plate. Each well contains a 20 µL lyophilized triplex reaction.
- Bulk Vials (~65 rxns per order): Each order consists of a single bulk vial, 675 µL of DNase/RNase free molecular grade water, and a 1 mL transfer pipette.
All form factors include Biomeme’s lyophilized RNA Extraction and RT-PCR Process Control (“RPC” - MS2 bacteriophage).
If you're looking for more of a turnkey solution, check out our SARS-CoV-2 Starter Kits which include everything you would need to collect and prepare your sample through interpreting results.
If you're looking to combine both sample extraction and testing, check out our SARS-CoV-2 Test Kits.
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.